Qiantang Longyue raises hundreds of millions of yuan in Series B for drug-delivery devices

What's the deal? Qiantang Longyue BiotechnologyDealroom has a profile for this one. Try Dealroom → has raised several hundred million yuan in a Series B round, the company announced in September 2026. Huimei CapitalDealroom has a profile for this one. Try Dealroom → led the round, with Zhejiang University Qizhen Venture CapitalDealroom has a profile for this one. Try Dealroom → and Chenyuan Venture Capital participating.

What does it do? Qiantang Longyue supplies customised drug-delivery device solutions. It develops and produces novel drug-delivery systems, high-end pharmaceutical packaging, and drug-device combination products.

The signal: Investor appetite for specialised drug-delivery and device makers points to demand for the supporting infrastructure behind new therapies, not just the drugs themselves.

Image credit: UCL Engineering